Opposing effects of acute versus chronic inhibition of p53 on decitabine’s efficacy in myeloid neoplasms

Decitabine is a DNA methyltransferase inhibitor and is considered a promising drug to treat myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) with p53 mutations. However, whether loss of p53 in fact increases the response of MDS/AML cells to decitabine remains unclear. In this study,...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Sci Rep
Главные авторы: Tamura, Moe, Yonezawa, Taishi, Liu, Xiaoxiao, Asada, Shuhei, Hayashi, Yasutaka, Fukuyama, Tomofusa, Tanaka, Yosuke, Kitamura, Toshio, Goyama, Susumu
Формат: Artigo
Язык:Inglês
Опубликовано: Nature Publishing Group UK 2019
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6547685/
https://ncbi.nlm.nih.gov/pubmed/31160638
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-019-44496-6
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы